Mankind Pharma
add_icon

Mankind Pharma

2,000.00
-0.80
(-0.04%)
Market Cap
82,561.01 Cr
PE Ratio
45.82
Volume
11,85,624.00
Day High - Low
2,047.40 - 1,966.70
52W High-Low
2,716.50 - 1,995.20
hide
Key Fundamentals
Add Ratio
split_icon_default
Market Cap
82,561.01 Cr
EPS
49.28
PE Ratio
45.82
PB Ratio
5.40
Book Value
370.27
EBITDA
3,554.70
Dividend Yield
0.00 %
Industry
Healthcare
Return on Equity
13.77
Debt to Equity
0.37
Analyst Rating and Forecast
- By Refinitiv from17 analysts
BUY
Analysts have suggested that investors can buy this stock
Buy
Buy+64.71 %
+64.71 %
Hold
Hold+17.65 %
+17.65 %
Sell
Sell+17.65 %
+17.65 %
Forecast For
Actual

Company News

View All News
Caret
positive
Mankind Pharma has acquired exclusive rights to manufacture, market and distribute Rivotril brand from Roche for the Indian market, strengthening its CNS therapy portfolio with this clonazepam reference brand.
neutral
Mankind Pharma's board approved allotment of 23,256 equity shares to eligible employees under ESOP Plan 2022, increasing paid-up capital to ₹41,28,28,328 with exercise price of ₹860 per share.
neutral
Mankind Pharma responds to BSE inquiry about increased trading volume, attributing it to market conditions while confirming compliance with disclosure norms.
View more
Competitors
LTP
Market Cap (₹ Cr.)
P/E Ratio
Revenue (₹ Cr.)
YoY Revenue Growth %
Net Profit (₹ Cr.)
YoY Profit Growth %
RSI
1,777.10
#1 4,26,385.82
38.21
#1 54,729.00
9.71
#1 10,980
16.07
53.49
6,100.00
1,61,935.83
64.01
9,712.00
18.67
2,191
-1.02
43.80
4,270.20
1,44,522.97
62.70
11,539.40
6.99
1,911
26.24
50.03
1,298.90
1,08,410.14
19.25
33,741.20
16.73
5,725
-15.28
53.38
2,322.50
1,06,091.52
22.06
22,909.50
13.74
3,306
#1 37.44
56.84
1,256.40
1,01,488.45
22.07
28,409.50
7.12
5,291
-57.18
31.85
890.50
89,605.14
#1 17.54
23,511.00
18.55
4,615
-0.32
45.58
2,000.00
#8 82,561.01
#8 45.82
#8 12,744.20
#1 20.90
#9 2,007
#4 7.65
37.22
1,291.40
75,004.72
20.80
32,345.60
9.43
3,484
7.59
60.75
5,257.50
62,861.30
25.87
13,458.30
3.70
2,216
1.90
37.74
Growth Rate
Revenue Growth
20.90 %
Net Income Growth
3.39 %
Cash Flow Change
12.12 %
ROE
-32.07 %
ROCE
-46.01 %
EBITDA Margin (Avg.)
5.21 %

Quarterly Financial Results

Quarterly Financials
Mar 2022
Jun 2022
Sept 2022
Dec 2022
Mar 2023
Jun 2023
Sept 2023
Dec 2023
Mar 2024
Jun 2024
Sept 2024
Dec 2024
Mar 2025
Jun 2025
Sept 2025
Dec 2025
Revenue
1,764
2,200
2,457
2,130
2,103
2,642
2,772
2,682
2,517
2,976
3,173
3,286
3,333
3,653
3,791
3,643
Expenses
1,441
1,724
1,835
1,654
1,636
1,924
2,025
2,000
1,836
2,196
2,217
2,383
2,401
2,724
2,776
2,754
EBITDA
323
476
622
477
467
718
746
681
681
780
956
903
933
930
1,016
889
Operating Profit %
17 %
21 %
24 %
21 %
20 %
25 %
25 %
23 %
24 %
23 %
28 %
26 %
22 %
24 %
25 %
23 %
Depreciation
47
78
79
85
85
87
97
110
100
103
101
187
231
219
222
223
Interest
13
16
10
13
5
6
9
9
9
11
7
221
191
171
170
157
Profit Before Tax
263
382
533
379
377
625
641
562
572
666
849
495
511
541
624
509
Tax
70
84
110
83
84
130
130
103
95
123
190
111
86
96
104
95
Net Profit
193
298
423
296
294
494
511
460
477
543
659
385
425
445
520
414
EPS in ₹
4.74
7.30
10.48
7.09
7.13
12.15
12.51
11.33
11.76
13.39
16.31
9.46
10.19
10.62
12.39
9.90

Balance Sheet

Balance Sheet
2021
2022
2023
2024
2025
Total Assets
6,373
9,148
9,715
11,963
27,760
Fixed Assets
1,664
3,588
4,251
4,545
19,005
Current Assets
3,907
4,407
4,328
6,568
6,988
Capital Work in Progress
372
702
550
282
826
Investments
1,512
1,110
1,346
2,568
2,042
Other Assets
2,824
3,749
3,568
4,568
5,887
Total Equity & Liabilities
6,373
9,148
9,715
11,963
27,760
Current Liabilities
1,353
2,624
1,863
2,120
5,664
Non Current Liabilities
156
208
229
268
7,528
Total Equity
4,863
6,316
7,623
9,576
14,568
Reserve & Surplus
4,682
6,115
7,395
9,323
14,291
Share Capital
40
40
40
40
41

Cash Flow

Cash Flow
2020
2021
2022
2023
2024
2025
Net Cash Flow
103
-92
156
22
77
22
Investing Activities
-436
-1,222
-1,369
-1,052
-2,081
-12,624
Operating Activities
1,070
1,137
920
1,813
2,152
2,413
Financing Activities
-531
-8
605
-740
5
10,233

Share Holding

% Holding
Sept 2022
Mar 2023
May 2023
Jun 2023
Sept 2023
Dec 2023
Mar 2024
Jun 2024
Sept 2024
Dec 2024
Mar 2025
Jun 2025
Sept 2025
Dec 2025
Promoter
79.00 %
76.50 %
76.50 %
76.50 %
76.50 %
76.50 %
74.88 %
74.87 %
74.87 %
72.71 %
72.70 %
72.68 %
72.67 %
72.66 %
FIIs
0.00 %
0.00 %
0.00 %
0.00 %
0.00 %
0.00 %
9.87 %
11.58 %
12.37 %
13.34 %
12.92 %
13.07 %
12.84 %
11.34 %
DIIs
0.00 %
2.64 %
2.64 %
4.64 %
4.39 %
9.49 %
11.14 %
9.95 %
9.90 %
11.06 %
11.48 %
11.50 %
11.92 %
13.25 %
Government
0.00 %
0.00 %
0.00 %
0.00 %
0.00 %
0.00 %
0.00 %
0.00 %
0.00 %
0.00 %
0.00 %
0.00 %
0.00 %
0.00 %
Public / Retail
0.00 %
4.15 %
4.15 %
1.02 %
1.11 %
1.14 %
1.22 %
1.46 %
1.55 %
1.60 %
1.64 %
1.52 %
1.36 %
1.52 %
Others
21.00 %
16.71 %
16.71 %
17.83 %
18.00 %
12.87 %
2.89 %
2.15 %
1.31 %
1.30 %
1.26 %
1.23 %
1.21 %
1.23 %
No of Share Holders
17
4,02,322
4,02,322
1,31,918
1,34,731
1,27,449
1,35,116
1,53,450
1,63,854
1,72,431
1,80,597
1,79,549
1,70,347
1,77,539

Announcements

Announcement under Regulation 30 (LODR)-Press Release / Media Release2 days ago
Announcement under Regulation 30 (LODR)-Allotment of ESOP / ESPS4 days ago
Clarification Submitted By Mankind Pharma LimitedFeb 27, 2026
Clarification sought from Mankind Pharma LtdFeb 27, 2026
Announcement Under Regulation 30 Of SEBI (LODR) Regulations 2015Feb 26, 2026
Announcement under Regulation 30 (LODR)-Credit RatingFeb 24, 2026
Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - IntimationFeb 18, 2026
Announcement Under Regulation 30 Of SEBI (LODR) Regulations 2015Feb 16, 2026
Disclosure Under Regulation 30 Of The SEBI (Listing Obligations And Disclosure Requirements) Regulations 2015Feb 09, 2026
Announcement under Regulation 30 (LODR)-Earnings Call TranscriptFeb 09, 2026
Announcement under Regulation 30 (LODR)-Newspaper PublicationFeb 04, 2026
Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - IntimationFeb 04, 2026
Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - OutcomeFeb 03, 2026
Compliances-Reg. 54 - Asset Cover details Feb 03, 2026
Announcement under Regulation 30 (LODR)-Investor PresentationFeb 03, 2026
Announcement under Regulation 30 (LODR)-Press Release / Media ReleaseFeb 03, 2026
Board Meeting Outcome for Outcome Of Board Meeting Of Financial Results For Q3 FY26Feb 03, 2026
Financial Result For The Quarter And Nine Months Ended December 31 2025Feb 03, 2026
Announcement under Regulation 30 (LODR)-Credit RatingJan 16, 2026
Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - IntimationJan 16, 2026
Board Meeting Intimation for Approval Of Unaudited Standalone And Consolidated Financial Results Of The CompanyJan 09, 2026
Compliances-Certificate under Reg. 74 (5) of SEBI (DP) Regulations 2018Jan 05, 2026
Closure of Trading WindowDec 24, 2025
Closure of Trading WindowDec 24, 2025
Intimation Under Regulation 30 Of The SEBI (Listing Obligations And Disclosure Requirements) Regulations 2015 (Listing Regulations)Dec 10, 2025
Intimation Regarding ESG RatingDec 10, 2025
Intimation Regarding ESG RatingNov 28, 2025
Announcement under Regulation 30 (LODR)-AllotmentNov 26, 2025
Intimation Under Regulation 30 Of SEBI (Listing Obligations & Disclosure Requirements) Regulations 2015Nov 16, 2025
Intimation Under Regulation 30 Of The SEBI (Listing Obligations And Disclosure Requirements) Regulations 2015Nov 15, 2025
Announcement under Regulation 30 (LODR)-Credit RatingNov 13, 2025
Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - IntimationNov 13, 2025
Announcement under Regulation 30 (LODR)-Earnings Call TranscriptNov 11, 2025
Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - IntimationNov 07, 2025
Announcement under Regulation 30 (LODR)-Newspaper PublicationNov 07, 2025
Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - OutcomeNov 06, 2025
Financial Results For The Quarter And Half Year Ended 30Th September 2025Nov 06, 2025
Announcement under Regulation 30 (LODR)-Press Release / Media ReleaseNov 06, 2025
Announcement under Regulation 30 (LODR)-Investor PresentationNov 06, 2025
Board Meeting Outcome for Outcome Of Board MeetingNov 06, 2025
Intimation Regarding ESG RatingNov 04, 2025
Intimation Regarding ESG RatingOct 29, 2025
Announcement under Regulation 30 (LODR)-Credit RatingOct 29, 2025
Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - IntimationOct 29, 2025
Board Meeting Intimation for Approval Of Financial Results For The Quarter And Half Year Ended On September 30 2025Oct 27, 2025
Announcement under Regulation 30 (LODR)-Updates on AcquisitionOct 10, 2025
Compliances-Certificate under Reg. 74 (5) of SEBI (DP) Regulations 2018Oct 04, 2025
Closure of Trading WindowSep 25, 2025
Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - IntimationSep 15, 2025
Intimation Under Regulation 30 Of The SEBI (Listing Obligations And Disclosure Requirements) Regulations 2015Sep 10, 2025

Mutual Fund Holdings

Funding HouseCurrent Holding %1M Change1M Change %3M Change %Last 6M Trend
Baroda BNP Paribas Health and Wellness Fund Direct-Growth
1.19%
-160000
-6.22%
-5.92%
Canara Robeco Multi Asset Allocation Fund Direct-Growth
0.00%
-54000
-0.90%
-1.15%
Bandhan Healthcare Fund Direct - Growth
3.43%
-7000
-0.52%
-0.41%
JioBlackRock Sector Rotation Fund Direct - Growth
0.19%
925
0.19%
0.19%
JioBlackRock Nifty Midcap 150 Index Fund Direct-Growth
0.67%
518
0.03%
0.03%
Tata Nifty Midcap 150 Index Fund Direct-Growth
0.67%
363
0.02%
0.02%
PGIM India Multi Asset Allocation Fund Direct - Growth
0.88%
240
-0.02%
-0.28%
DSP Nifty Healthcare Index Fund Direct-Growth
2.53%
204
-0.03%
0.00%
Kotak Nifty Midcap 150 Index Fund Direct - Growth
0.67%
73
0.03%
0.02%
Nippon India Nifty India Manufacturing Index Fund Direct - Growth
0.66%
46
0.01%
0.00%
Navi Nifty MidSmallcap 400 Index Fund Direct - Growth
0.44%
-27
0.02%
0.02%
DSP Nifty Midcap 150 Index Fund Direct - Growth
0.67%
24
0.03%
0.02%
Groww Nifty Midcap 150 Index Fund Direct - Growth
0.67%
14
0.03%
0.02%
DSP Nifty 500 Index Fund Direct-Growth
0.13%
-4
0.01%
0.13%
Motilal Oswal BSE 1000 Index Fund Direct-Growth
0.12%
3
0.01%
0.01%
Invesco India Multicap Fund Direct-Growth
0.00%
0
0.00%
0.00%
Sundaram ELSS Tax Saver Fund Direct
0.00%
0
0.00%
0.00%
Axis Aggressive Hybrid Fund Direct-Growth
0.79%
0
0.00%
0.04%
Axis Arbitrage Fund Direct-Growth
0.00%
0
0.00%
0.00%
Axis Balanced Advantage Fund Direct-Growth
0.36%
0
0.00%
-0.12%
Axis Business Cycles Fund Direct-Growth
1.32%
0
0.00%
0.07%
Axis ELSS Tax Saver Direct Plan-Growth
0.94%
0
0.00%
0.05%
Axis Equity Savings Fund Direct-Growth
0.00%
0
0.00%
0.00%
Axis ESG Integration Strategy Fund Direct-Growth
0.00%
0
0.00%
0.00%
Axis Flexi Cap Fund Direct-Growth
1.88%
0
0.00%
0.07%

Technical Indicators

RSI(14)
Neutral
37.28
ATR(14)
Volatile
64.36
STOCH(9,6)
Neutral
20.22
STOCH RSI(14)
Oversold
5.10
MACD(12,26)
Bearish
-19.58
ADX(14)
Weak Trend
19.37
UO(9)
Bearish
37.68
ROC(12)
Downtrend And Accelerating
-10.90
WillR(14)
Oversold
-98.00

About Mankind Pharma

Mankind Pharma Limited is an Indian pharmaceutical company incorporated in 1991. It develops, manufactures, and markets pharmaceutical formulations and consumer healthcare products. The company operates in various therapeutic areas including anti-infectives, cardiovascular, gastrointestinal, anti-diabetic, neuro/CNS, vitamins/minerals/nutrients, and respiratory. Mankind Pharma entered the consumer healthcare segment in 2007 and has since...more
Listing Date
09 May, 2023(2 Years, 39 days)
Chairperson NameRAMESH CHAND JUNEJA